Identification of prognostic long intergenic non‑coding RNAs as competing endogenous RNAs with KRAS mutations in colorectal cancer

Xu,Jun; Huang,Qiu-Yun; Ge,Cun-Jin

doi:10.3892/ol.2021.12978

Identification of prognostic long intergenic non‑coding RNAs as competing endogenous RNAs with KRAS mutations in colorectal cancer

Authors:
- Jun Xu
- Qiu-Yun Huang
- Cun-Jin Ge
View Affiliations

Affiliations: Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei 443000, P.R. China, Department of Gastroenterology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei 443000, P.R. China
Published online on: August 9, 2021 https://doi.org/10.3892/ol.2021.12978
Article Number: 717
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is recognized as a common type of human cancer, and KRAS mutations are correlated with poor CRC survival outcomes. The evaluation and prediction of CRC results remain challenging. In the present study, RNA sequencing and clinical data from The Cancer Genome Atlas were used to identify KRAS mutation‑related prognostic long intergenic non‑coding RNAs (lincRNAs) in CRC. Significantly dysregulated lincRNAs and independent prognostic lincRNAs with KRAS mutations in CRC were identified. Two lincRNAs with KRAS mutations, LINC00265 and AL390719.2, were selected as key prognostic lincRNAs for both 10‑ and 5‑year survival rates. In addition, competing endogenous (ce)RNA models were constructed to comprehensively assess the oncogenic performance of the two key lincRNAs. The ceRNA models suggested that LINC00265 and AL390719.2 are critical for the cell cycle and cancer pathways. Finally, reverse transcription‑quantitative PCR was used to validate the ceRNA models in 12 pairs of CRC tissue samples. These prognostic lincRNAs may provide novel biomarkers for the prognostic prediction of CRC. The ceRNA model may also demonstrate the underlying mechanism of these lincRNAs in CRC.

View Figures

View References

1	Nasseri Y and Langenfeld SJ: Imaging for colorectal cancer. Surg Clin North Am. 97:503–513. 2017. View Article : Google Scholar : PubMed/NCBI
2	Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:1972017. View Article : Google Scholar
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Patel SG and Ahnen DJ: Colorectal cancer in the young. Curr Gastroenterol Rep. 20:152018. View Article : Google Scholar : PubMed/NCBI
5	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
6	Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B and Russo A: Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 99:150–157. 2016. View Article : Google Scholar : PubMed/NCBI
7	Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 5:689–698. 2005. View Article : Google Scholar : PubMed/NCBI
9	Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, et al: Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell. 28:529–540. 2015. View Article : Google Scholar : PubMed/NCBI
10	Mattick JS and Rinn JL: Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 22:5–7. 2015. View Article : Google Scholar : PubMed/NCBI
11	Talyan S, Andrade-Navarro MA and Muro EM: Identification of transcribed protein coding sequence remnants within lincRNAs. Nucleic Acids Res. 46:8720–8729. 2018. View Article : Google Scholar : PubMed/NCBI
12	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
13	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Cho KB, Li Y, Tao G, Xie Z and Guo B: Long noncoding RNA (lncRNA)-mediated competing endogenous rna networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 20:57582019. View Article : Google Scholar : PubMed/NCBI
15	Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y and Chen Y: The emerging function and mechanism of ceRNAs in cancer. Trends Genet. 32:211–224. 2016. View Article : Google Scholar : PubMed/NCBI
17	Song YX, Sun JX, Zhao JH, Yang YC, Shi JX, Wu ZH, Chen XW, Gao P, Miao ZF and Wang ZN: Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun. 8:2892017. View Article : Google Scholar : PubMed/NCBI
18	Wong CC, Qian Y, Li X, Xu J, Kang W, Tong JH, To KF, Jin Y, Li W, Chen H, et al: SLC25A22 promotes proliferation and survival of colorectal cancer cells With KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate. Gastroenterology. 151:945–960.e6. 2016. View Article : Google Scholar : PubMed/NCBI
19	Song Y, Chen QT and He QQ: Identification of key transcription factors in endometrial cancer by systems bioinformatics analysis. J Cell Biochem. 120:15443–15454. 2019. View Article : Google Scholar : PubMed/NCBI
20	Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, Turnbaugh PJ, Lander ES, Mitzenmacher M and Sabeti PC: Detecting novel associations in large data sets. Science. 334:1518–1524. 2011. View Article : Google Scholar : PubMed/NCBI
21	Tripathi S, Pohl MO, Zhou Y, Rodriguez-Frandsen A, Wang G, Stein DA, Moulton HM, DeJesus P, Che J, Mulder LC, et al: Meta- and orthogonal integration of influenza ‘OMICs’ data defines a role for UBR4 in virus budding. Cell Host Microbe. 18:723–735. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zheng Y, Fang YC and Li J: PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 18:5399–5407. 2019.PubMed/NCBI
23	Tai P, Yu E, Cserni G, Vlastos G, Royce M, Kunkler I and Vinh-Hung V: Minimum follow-up time required for the estimation of statistical cure of cancer patients: Verification using data from 42 cancer sites in the SEER database. BMC Cancer. 5:482005. View Article : Google Scholar : PubMed/NCBI
24	Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L and Rusu C: KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer-practical implications for the clinician. Radiol Oncol. 53:265–274. 2019. View Article : Google Scholar
25	Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K, Meskinyte-Kausiliene E, Stankevicius V and Valius M: KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol. 34:262017. View Article : Google Scholar : PubMed/NCBI
26	Porru M, Pompili L, Caruso C, Biroccio A and Leonetti C: Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities. J Exp Clin Cancer Res. 37:572018. View Article : Google Scholar : PubMed/NCBI
27	Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z and Zhang LW: Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 20:2285–2295. 2016.PubMed/NCBI
28	Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, Wang XW and Oberdoerffer P: Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth. Nat Commun. 8:1372017. View Article : Google Scholar : PubMed/NCBI
29	Cui K, Liu C, Li X, Zhang Q and Li Y: Comprehensive characterization of the rRNA metabolism-related genes in human cancer. Oncogene. 39:786–800. 2020. View Article : Google Scholar : PubMed/NCBI
30	Li X, Li B, Ran P and Wang L: Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma. Oncol Lett. 16:5697–5708. 2018.PubMed/NCBI
31	Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD and Ran ZH: MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 106:1320–1330. 2012. View Article : Google Scholar : PubMed/NCBI
32	Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
33	Guo H, Hu X, Ge S, Qian G and Zhang J: Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. Int J Biochem Cell Biol. 44:1465–1472. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, Moyer MP, Zhang HZ, Chen HQ, Liang Y and Qin HL: SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 229:12–24. 2013. View Article : Google Scholar : PubMed/NCBI
35	Liu C, Kelnar K, Vlassov AV, Brown D, Wang J and Tang DG: Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 72:3393–3404. 2012. View Article : Google Scholar : PubMed/NCBI
36	Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT and El-Deiry WS: miR-6883 family miRNAs target CDK4/6 to induce G₁ phase cell-cycle arrest in colon cancer cells. Cancer Res. 77:6902–6913. 2017. View Article : Google Scholar : PubMed/NCBI
37	Yang R, Wei M, Yang F, Sheng Y and Ji L: Diosbulbin B induced G₂/M cell cycle arrest in hepatocytes by miRNA-186-3p and miRNA-378a-5p-mediated the decreased expression of CDK1. Toxicol Appl Pharmacol. 357:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
38	Spiller F, Medina-Pritchard B, Abad MA, Wear MA, Molina O, Earnshaw WC and Jeyaprakash AA: Molecular basis for Cdk1-regulated timing of Mis18 complex assembly and CENP-A deposition. EMBO Rep. 18:894–905. 2017. View Article : Google Scholar : PubMed/NCBI
39	Lopez-Mejia IC, Lagarrigue S, Giralt A, Martinez-Carreres L, Zanou N, Denechaud PD, Castillo-Armengol J, Chavey C, Orpinell M, Delacuisine B, et al: CDK4 phosphorylates AMPKα2 to inhibit its activity and repress fatty acid oxidation. Mol Cell. 68:336–349.e6. 2017. View Article : Google Scholar : PubMed/NCBI